160 related articles for article (PubMed ID: 35344659)
1. Foscarnet-Type Inorganic-Organic Hybrid Nanoparticles for Effective Antiviral Therapy.
Khorenko M; Rand U; Cicin-Sain L; Feldmann C
ACS Biomater Sci Eng; 2022 Apr; 8(4):1596-1603. PubMed ID: 35344659
[TBL] [Abstract][Full Text] [Related]
2. Contrasting effects of W781V and W780V mutations in helix N of herpes simplex virus 1 and human cytomegalovirus DNA polymerases on antiviral drug susceptibility.
Piret J; Goyette N; Eckenroth BE; Drouot E; Götte M; Boivin G
J Virol; 2015 Apr; 89(8):4636-44. PubMed ID: 25673718
[TBL] [Abstract][Full Text] [Related]
3. Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases.
Zarrouk K; Zhu X; Goyette N; Piret J; Shi R; Boivin G
Antiviral Res; 2021 Apr; 188():105046. PubMed ID: 33588012
[TBL] [Abstract][Full Text] [Related]
4. Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet.
Zarrouk K; Zhu X; Pham VD; Goyette N; Piret J; Shi R; Boivin G
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0039021. PubMed ID: 33875432
[TBL] [Abstract][Full Text] [Related]
5. Neoglycolipid conjugates of foscarnet with enhanced antiviral activity in cells infected with human cytomegalovirus and herpes simplex virus type 1.
Maloisel JL; Pring BG; Tidén AK; Dypbukt J; Ljungdahl-Ståhle E
Antivir Chem Chemother; 1999 Nov; 10(6):333-45. PubMed ID: 10628809
[TBL] [Abstract][Full Text] [Related]
6. Fluorescent Sulfonate-Based Inorganic-Organic Hybrid Nanoparticles for Staining and Imaging.
Poß M; Zittel E; Meschkov A; Schepers U; Feldmann C
Bioconjug Chem; 2018 Aug; 29(8):2818-2828. PubMed ID: 30004681
[TBL] [Abstract][Full Text] [Related]
7. Highly selective organ distribution and cellular uptake of inorganic-organic hybrid nanoparticles customized for the targeted delivery of glucocorticoids.
Kaiser TK; Khorenko M; Moussavi A; Engelke M; Boretius S; Feldmann C; Reichardt HM
J Control Release; 2020 Mar; 319():360-370. PubMed ID: 31923534
[TBL] [Abstract][Full Text] [Related]
8. Alkylthioglycerol prodrugs of foscarnet: synthesis, oral bioavailability and structure-activity studies in human cytomegalovirus-, herpes simplex virus type 1- and human immunodeficiency virus type 1-infected cells.
Beadle JR; Kini GD; Aldern KA; Gardner MF; Wright KN; Richman DD; Hostetler KY
Antivir Chem Chemother; 1998 Jan; 9(1):33-40. PubMed ID: 9875375
[TBL] [Abstract][Full Text] [Related]
9. Genotypic characterization of the DNA polymerase and sensitivity to antiviral compounds of foscarnet-resistant herpes simplex virus type 1 (HSV-1) derived from a foscarnet-sensitive HSV-1 strain.
Saijo M; Suzutani T; Morikawa S; Kurane I
Antimicrob Agents Chemother; 2005 Feb; 49(2):606-11. PubMed ID: 15673740
[TBL] [Abstract][Full Text] [Related]
10. Alkoxy propane prodrugs of foscarnet: effect of alkyl chain length on in vitro antiviral activity in cells infected with HIV-1, HSV-1 and HCMV.
Kini GD; Beadle JR; Xie H; Aldern KA; Richman DD; Hostetler KY
Antiviral Res; 1997 Sep; 36(1):43-53. PubMed ID: 9330760
[TBL] [Abstract][Full Text] [Related]
11. Preparation, characterization and in vitro antiviral activity evaluation of foscarnet-chitosan nanoparticles.
Russo E; Gaglianone N; Baldassari S; Parodi B; Cafaggi S; Zibana C; Donalisio M; Cagno V; Lembo D; Caviglioli G
Colloids Surf B Biointerfaces; 2014 Jun; 118():117-25. PubMed ID: 24742953
[TBL] [Abstract][Full Text] [Related]
12. Hypersusceptibility of Human Cytomegalovirus to Foscarnet Induced by Mutations in Helices K and P of the Viral DNA Polymerase.
Zarrouk K; Pham VD; Piret J; Shi R; Boivin G
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015044
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV(r) virus.
Saijo M; Yasuda Y; Yabe H; Kato S; Suzutani T; De Clercq E; Niikura M; Maeda A; Kurane I; Morikawa S
J Med Virol; 2002 Sep; 68(1):99-104. PubMed ID: 12210436
[TBL] [Abstract][Full Text] [Related]
14. The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase.
Andrei G; Gillemot S; Topalis D; Snoeck R
J Infect Dis; 2018 Feb; 217(5):790-801. PubMed ID: 29186456
[TBL] [Abstract][Full Text] [Related]
15. A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet.
Ducancelle A; Champier G; Alain S; Petit F; Le Pors MJ; Mazeron MC
Antivir Ther; 2006; 11(4):537-40. PubMed ID: 16856628
[TBL] [Abstract][Full Text] [Related]
16. Antiviral drug resistance in herpesviruses other than cytomegalovirus.
Piret J; Boivin G
Rev Med Virol; 2014 May; 24(3):186-218. PubMed ID: 24604770
[TBL] [Abstract][Full Text] [Related]
17. Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection.
Boutolleau D; Canestri A; Burrel S; Wirden M; Seang S; Clavel-Osorio C; Marcelin AG; Katlama C; Agut H
J Clin Virol; 2012 Jun; 54(2):194-6. PubMed ID: 22398036
[TBL] [Abstract][Full Text] [Related]
18. Novel Method Based on Real-Time Cell Analysis for Drug Susceptibility Testing of Herpes Simplex Virus and Human Cytomegalovirus.
Piret J; Goyette N; Boivin G
J Clin Microbiol; 2016 Aug; 54(8):2120-7. PubMed ID: 27252463
[TBL] [Abstract][Full Text] [Related]
19. Multifunctional phosphate-based inorganic-organic hybrid nanoparticles.
Heck JG; Napp J; Simonato S; Möllmer J; Lange M; Reichardt HM; Staudt R; Alves F; Feldmann C
J Am Chem Soc; 2015 Jun; 137(23):7329-36. PubMed ID: 26018463
[TBL] [Abstract][Full Text] [Related]
20. Murine cytomegalovirus resistant to antivirals has genetic correlates with human cytomegalovirus.
Scott GM; Ng HL; Morton CJ; Parker MW; Rawlinson WD
J Gen Virol; 2005 Aug; 86(Pt 8):2141-2151. PubMed ID: 16033961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
